Oral treatment with plecanatide or dolcanatide attenuates visceral hypersensitivity via activation of guanylate cyclase-C in rat models

Figure 5 Design and results of the TNBS-induced visceral hypersensitivity models. A: Schematic depicting the sequence of test sessions and treatments to evaluate visceral hypersensitivity induced by TNBS rat models. Effects of oral administration of plecanatide or dolcanatide as compared with vehicle on the increase in abdominal contractions to colorectal distention (CRD) during testing conducted four days after intrarectal administration of TNBS. Doses of 0.01 and 0.05 mg/kg of plecanatide (B) or dolcanatide (C) reduced the rate of muscular contractions toward levels observed in the vehicle group prior to TNBS administration. Data are the mean ± SEM (n = 8 rats/group). ^aP < 0.05, ^bP < 0.01 as compared to the values for the post-trinitrobenzene sulfonic acid vehicle group. SEM: Standard error of the mean; TNBS: Trinitrobenzene sulfonic acid.